Moleculin Biotech watched its shares climb on Thursday after the company announced a new breakthrough for cancer treatment.
Chris Lange
The top analyst upgrades, downgrades and other research calls from Wednesday include Alcoa, Extreme Networks, Gilead Sciences, MGIC, Micron, Noble Energy, Twitter, U.S. Steel and Wendy's
Jon C. Ogg
Moleculin Biotech plans to list up to 2 million shares at an estimated $5.50 apiece in an IPO valued at up to $11 million.
Chris Lange
These are some of the top analyst downgrades or cautious research calls we have seen this Tuesday morning before the market opens: Accenture (ACN) Cut to Hold at Argus. Freeport-McMoRan (FCX) Cut to...
Douglas A. McIntyre
Metabasis Therapeutics (NASDAQ:MBRX) announced after the close today that its MB07133 has been granted orphan medicinal product status for the treatment of hepatocellular carcinoma (primary liver...
Douglas A. McIntyre
Metabasis Therapeutics (MBRX) is off 56% to $3 after its diabetes drug candidate CS-917 failed to significantly lower blood sugar in a mid-stage trial. The company has traded as high as $8.64 in the...
Douglas A. McIntyre
(AAI) AirTran load factor rose 6.7% to 68.5%.(BEAS) BEA Systems stake raised to 11% by Carl Icahn.(BOBE) Bob Evans s-s-s rose 0.4%.(CPST) Capstone Turbine received a microturbine order for for $3.8...
Douglas A. McIntyre
From BioHealth Investor Biotechnology HESKA CORPORATION [HSKA] +10.67% IDERA PHARMACEUTICAL [IDP] +8.76% NUTRITION 21 INC [NXXI] +8.00% METABASIS THERAPEUTI [MBRX] +5.19% CYTORI THERAPEUTICS [CYTX]...
Douglas A. McIntyre